Author: Editor

There are two primary routes of therapy for amyloidosis: treating the underlying plasma cell dyscrasia, and clearing amyloid deposits. In this insightful interview, recorded at the Myeloma 2017 meeting in Edinburgh, UK, Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, from University College London, London, UK, gives an overview of some of the most exciting data in the field, including bortezomib combinations, single agent daratumumab, and ixazomib, which have shown great potential. Dr Wechalekar highlights ongoing studies of monoclonal antibodies that act through clearing amyloid deposits, including a highly anticipated anti-SAP antibody being developed (NCT03044353), and NEOD001, currently being investigated in…

Key to the treatment of amyloidosis is being able to discern the severity of illness, so that the patient can be prescribed an appropriate therapy course. In this interview, Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, from University College London, London, UK, discusses the latest advancements in patient risk stratification, new imaging agents to observe amyloid deposits in soft tissues, and novel treatments for the condition. These include the recent monitoring of von Willebrand factor as a prognostic marker, and immunotherapy drugs currently in clinical trials. This video was recorded at the Myeloma 2017 meeting in Edinburgh, UK.

Prostate cancer therapies have developed greatly in recent years, with many more options for treatment available that can provide patients with a higher quality of life for years after diagnosis. Here, Hilary Baker of University College London Hospitals NHS Foundation Trust, London, UK, summarizes the current strategies available to prostate cancer patients. This interview was recorded at the UK Oncology Nursing Society (UKONS) Annual Conference 2017 in Harrogate, UK.

A clinical nurse specialist plays a critical role in the treatment of a cancer patient. In this interview, Hilary Baker of University College London Hospitals NHS Foundation Trust, London, UK, gives an overview of her talk at the UK Oncology Nursing Society (UKONS) Annual Conference 2017, Harrogate, UK, where she discussed the role of the CNS in mCRPC treatment, and the unique nature of the position as both a clinical assessor and a provider of psychological support to the patient.

Nathan Fowler, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses side effects of PI3K inhibitors at the 2017 International Workshop in Non-Hodgkin Lymphoma (iwNHL) in Vancouver, BC, Canada. Transaminitis is where transaminases are elevated in the liver. This usually occurs at the start of treatment, and has been found to go away once stopping and restarting treatment. Other side effects include inflammatory conditions, such as colitis and pneumonitis. It is recommended that patients who present with these side effects stop treatment, and undergo an infectious workup.

Idelalisib was the first phosphoinositide 3-kinase (PI3K) inhibitor to be used in lymphoma, which had remarkable responses on B-cell lymphomas as a single-agent. Nathan Fowler, MD at the University of Texas MD Anderson Cancer Center, Houston, TX talks about the different combination studies with idelalisib, and how we are trying to overcome toxicities found, by developing second-generation PI3K inhibitors, such as copanlisib, umbralisib, and duvelisib. Recorded at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2017 annual meeting, held in Vancouver, BC, Canada.

Marek Trneny, MD, from the Charles University, Prague, Czech Republic, discusses highlights from the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2017, held in Vancouver, BC, Canada. The PDX model in particular is important in terms of drug discovery and testing, and better understanding the mechanism of the disease and drug action.

John Kuruvilla, MD, FRCPC, from the Princess Margaret Cancer Centre, Toronto, Canada, discusses integrating treatments around autologous transplantation at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2017, held in Vancouver, BC, Canada. Phase III trials have shown that autologous transplantation is superior to conventional chemotherapy, however, more research needs to be carried out to determine how to integrate novel therapies around transplant, because a large proportion of patients dont respond to treatment before transplant. This has been successful in Hodgkin lymphoma so far, however, this has not been mirrored in non-Hodgkin lymphoma. CAR T-cell therapy has been shown to have…

John Kuruvilla, MD, FRCPC, from the Princess Margaret Cancer Centre, Toronto, Canada, discusses the development of IMiDs at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2017, held in Vancouver, BC, Canada. IMiDs have been shown to have single agent activity, particularly in lymphoma and myeloma. A novel compound being developed for diffuse large B-cell lymphoma is called CC122, shown to be well tolerated, and its administered as orally. It has also been tested in combination with a BTK inhibitor, an MTOR inhibitor, and with anti CD20 antibodies in the relapsed refractory setting. These will hopefully be put through Phase III…

The exciting field of proton beam therapy is still developing; thus, as its utilization in the UK increases there is a need for further research to ensure that it is used effectively and appropriately. Speaking from the 2017 National Cancer Research Institute (NCRI) Conference in Liverpool, UK, Anthony Zietman, MD, from the Massachusetts General Hospital, Boston, MA, discusses the current usage of proton beam radiation as a treatment for cancer within the UK, the benefits of this in terms of cost-saving and what further research is required moving forwards.

The introduction of new healthcare tools requires the careful navigation of social, political and economic pressures. In this interview, recorded at the 2017 National Cancer Research Institute (NCRI) Conference in Liverpool, UK, Anthony Zietman, MD, from the Massachusetts General Hospital, Boston, MA, discusses the challenges that were faced when establishing two UK centers for proton beam therapy. Dr Zietman also details the future questions that need to be explored regarding proton therapy. Furthermore, Dr Zietman provides an overview of the model of patient selection used for Denmarks emerging proton therapy system.

The uptake of proton beam therapy has been slower in the UK compared with other developed countries; however, this is now set to change. In this insightful interview, Anthony Zietman, MD, from the Massachusetts General Hospital, Boston, MA, discusses the future of proton beam therapy in the UK, highlighting affordability, as well as the ability of the UK to integrate any successor of proton beam therapy. This interview was recorded at the 2017 National Cancer Research Institute (NCRI) Conference, held in Liverpool, UK.

Since 2004, over 20 new proton beam centers, a type of radiation primarily identified as being effective in treating pediatric cancers, have been built in the USA. In this interview, Anthony Zietman, MD, from the Massachusetts General Hospital, Boston, MA, discusses how PSA testing and the increase in the number of men diagnosed with prostate cancer contributed to this. Dr Zietman highlights how the financial model in the USA is seeing this market quickly declining again. However, the UK has recently emerged with plans for two proton beam centers, which could provide the required evidence for the use of the…

Radiation therapy is well established as one of the three primary approaches to treating cancer; however, it comes with a number of issues. Here, Anthony Zietman, MD, of the Massachusetts General Hospital, Boston, MA, discusses these issues, and describes the pros and cons of proton beam therapy in comparison to standard radiotherapy, particularly in a pediatric setting. This video was recorded at the 2017 National Cancer Research Institute (NCRI) Conference, held in Liverpool, UK.

CAR-T cell therapy is an innovative new strategy that may revolutionize lymphoma treatment. Speaking from the 2017 National Cancer Research Institute (NCRI) Conference in Liverpool, UK, Graham Collins, MA, MBBs, MRCP, FRCPath, DPhil of the Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the effectiveness of CAR-T cell therapy in relapsed and refractory lymphoma, and reviews some of the pros and cons that may arise from the usage of CAR-T cells, including cost, ease of administration and toxicity.

New studies are constantly evolving the field of lymphoma research, with trials continuously striving to find more effective treatments. At the 2017 National Cancer Research Institute (NCRI) Conference in Liverpool, UK, Graham Collins, MA, MBBs, MRCP, FRCPath, DPhil of the Oxford University Hospitals NHS Foundation Trust, Oxford, UK, spoke to us about some of the most anticipated upcoming trial results in the field of lymphoma treatment. Among them include the ECHELON-1 trial (NCT01712490), comparing ABVD with AVD plus brentuximab vedotin in the treatment of advanced stage Hodgkin lymphoma, and the new antibody-drug conjugate ADCT-301, which targets CD25. Dr Collins reviews…

As the roles of various proteins within the human body become clearer, novel research can develop to produce effective therapies with a high specificity. In this video, Emery Bresnick, PhD, from the University of Wisconsin, Wisconsin, WI, speaking from the International Conference on Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Haematology (ESH), discusses the link between GATA2 and acute myeloid leukemia. Dr Bresnick touches upon the mechanism of action of the gene, the influence it has upon progenitor and stem cells, and the effects of coding and non-coding mutations of GATA2.

To efficiently produce effective therapies, it is necessary for experts within different specialties to collaborate. At the International Conference on Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Haematology (ESH), Emery Bresnick, PhD, from the University of Wisconsin, Wisconsin, WI, discusses the benefits of utilizing a collaborative research method in hematology-oncology, referencing insightful examples to exemplify this approach.

Immunotherapy has emerged in recent years as a promising lymphoma treatment, with exciting new drug classes being developed with innovative mechanisms of action. Here, Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil of the Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses various types of lymphoma treatment, including ADCC-activating monoclonal antibodies, antibody-drug conjugates, and traditional immunotherapies such as PD-1 inhibitors. Dr Collins reviews the efficacy of these drug types in both Hodgkin and non-Hodgkin lymphoma, and some of their specific subtypes, drawing conclusions from a range of sources, including the 2002 study by the French GELA group regarding the effectiveness…

As the finer details of how therapies interact within the body become clear, novel research to create more effective medications can occur. At the International Conference on Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Haematology (ESH), Christoph Plass, PhD, from the German Cancer Research Center, Heidelberg, Germany, discusses the use of epigenetic therapies to tackle acute myeloid leukemia and myelodysplastic syndromes. Dr Plass highlights the potential molecular mechanisms that these drugs utilize to promote the apoptosis of leukemic cells, referencing LTRs and treatment-induced non-annotated TSSs.

To produce safe and effective therapies for patients, novel research must first occur in cell culture systems. In this interview, Christoph Plass, PhD, from the German Cancer Research Center, Heidelberg, Germany, discusses his teams research into epigenetic therapies and provides us with an overview of the numerous potential benefits of improved understanding of the molecular mechanism of these therapies, highlighting potential diagnostic and prognostic biomarker identification. This interview was recorded at the International Conference on Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Haematology (ESH).

There are two well-known checkpoint inhibitors that have shown efficacy in relapses/refractory Hodgkin lymphoma, nivolumab and pembrolizumab, both PD-1 inhibitors. Here, John Kuruvilla, MD, FRCPC at the Princess Margaret Cancer Centre, Toronto, ON takes us through the existing data, such as efficacy, safety and remission rates. Recorded at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2017 meeting, held in Vancouver, BC, Canada.

Francine Foss, MD, from the Yale University School of Medicine, New Haven, CT, discusses targeting chemokines at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2017 meeting, held in Vancouver, BC, Canada. Chemokines are a group of molecules that are expressed in the microenvironment of T- and B-cell malignancies. The anti-CCR4 antibody has been developed, and there is now research into whether there is a role for other chemokine therapy in lymphoma. There is also the possibility for targeting specific chemokines that affect the growth of the tumor cell to be targeted, as well as those associated with migration and metastasis.

“Both targeted agents, such as brentuximab vedotin, and checkpoint inhibitors, such as pembrolizumab, have shown activity in a subset of patients with cutaneous T-cell lymphoma. Francine Foss, MD at the Yale University, New Haven, CT is using this disease as a model to assess the efficacy and mechanism of action of combining targeted agents with checkpoint inhibitors. Recorded at the International Workshop of Non-Hodgkin Lymphoma (iwNHL) 2017 meeting, held in Vancouver, BC, Canada.”

Dr. Jack West addresses the question of whether the data with various PD-1 and PD-L1 inhibitors in lung cancer management can be viewed as a class effect and whether these immune checkpoint inhibitors should be considered interchangeable.

Patients who are actively engaged with their diagnosis, treatment and symptoms now have an outlet to share their treatment journey and day-to-day experiences for research to help patients with MPNs. Hear Lindsey Whyte from the MPN Research Foundation, and Dr. Srdan Verstovsek from The University of Texas MD Anderson Cancer Center discuss how patients can contribute to the cancer community and scientific research by sharing their voice. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Neeraj Agarwal, MD Associate Professor of Medicine Director, Genitourinary Oncology Co-leader, Urologic Oncology Multidisciplinary Program Huntsman Cancer Institute, University of Utah discusses the treatment of metastatic renal cell carcinoma (mRCC) in the elderly at the 2017 Kidney Cancer Association symposium in Miami, FL.

Pavlos Msaouel MD, PhD Chief Fellow, Hematology/Oncology MD Anderson Cancer Center discusses Renal Medullary Carcinoma at the 2017 Kidney Cancer Association symposium in Miami, FL.

MOASC Educational Series 2017 roundtable discussion on oncology billing and the new challenges.

Remy Turner presents the options available to providers to follow-up on claims that have been submitted for payment. Timeliness and claim submission guidelines for follow-up forms will also be discussed.

Dawn Holcombe, MBA, FACMPE, ACHE DGH Consulting discusses Pharmacy Standards in transition and real at the MOASC Educational Series 2017

Elaine L. Towle, CMPE discusses MACRA and MIPS and an Oncology Billing Update: And Whats new for 2018? from the MOASC Educational Series November 9th, 2017.

Dr. Jack West reviews the implications of the PACIFIC trial that establishes a role for durvalumab immunotherapy in stage III NSCLC, and which will likely lead to some patients shifting away from surgery in favor of chemoradiation followed by durvalumab.

Christopher Wood, MD, Elizabeth Plimack, MD, Martin Voss, MD, Viraj Masters, MD, A. Ari Hakimi, MD consult on a several real world challenge kidney cancer cases at the 2017 Kidney Cancer Association symposium in Miami, FL.

Brian Shuch, MD Assistant Professor of Urology and Radiology Yale School of Medicine Genomic Heterogeneity and the Small Renal Mass discusses Genomic Heterogeneity and the Small Renal Mass at the 2017 Kidney Cancer Association symposium in Miami, FL.

Martin Voss, MD Memorial Sloan Kettering discusses Integrated Biomarker Analysis for 412 RCC patients Treated on the Phase 3 COMPARZ Trial at the 2017 Kidney Cancer Association symposium in Miami, FL.

Sumanta Kumar Pal, M.D City of Hope Cancer Center discusses IMmotion150: Novel Radiological Endpoints and Updated Data From a Randomized Phase II Trial Investigating Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma at the 2017 Kidney Cancer Association symposium in Miami, FL.

Comparative Genomic Profiling of Matched Maria Becerra, MD discusses Primary and Metastatic Tumors in Renal Cell Carcinoma at the 2017 Kidney Cancer Association symposium in Miami, FL.

Vadim S. Koshkin, MD Cleveland Clinic Taussig Cancer discusses Clinical Activity of Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma at the 2017 Kidney Cancer Association symposium in Miami, FL.

Christopher G. Wood, M. D., FACS Professor and Deputy Chairman Douglas E. Johnson, M. D. Endowed Professorship In Urology Department of Urology The University of Texas MD Anderson Cancer Center outlines Training Urologists To Be Experts In Renal Cell Carcinoma at the 2017 Kidney Cancer Association symposium in Miami, FL.

Ronald M. Bukowski, MD discusses Training Medical Oncologists to be Experts in RCC at the 2017 Kidney Cancer Association symposium in Miami, FL.

Martin Voss, MD Genitourinary Oncology Service Memorial Sloan Kettering Cancer Center, New York gives an Update on Genomic Classifiers in RCC at the 2017 Kidney Cancer Association symposium in Miami, FL.

Joshua M. Lang, MD University of Wisconsin School of Medicine and Public Health discusses Circulating Biomarkers in Clear Cell Renal Cell Carcinoma at the 2017 Kidney Cancer Association symposium in Miami, FL.

Payal Kapur, M.D. Associate Professor of Pathology and Urology, UTSW Group Leader Genitourinary Pathology, UTSW Kidney Cancer Program co-leader, Simmons Cancer Center discusses In Vivo Models of RCC Genetically engineered mouse models in ccRCC at the 2017 Kidney Cancer Association symposium in Miami, FL.

Leigh Ellis Ph.D. Assistant Professor Department of Oncologic Pathology Dana-Farber Cancer Institute Brigham and Womens Hospital Harvard Medical School discusses 3-dimensional (3D) Organoids for Renal Cell Carcinoma Research at the 2017 Kidney Cancer Association symposium in Miami, FL.

Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery Affiliate Member Department of Computational Biology discusses Cell line and PDX models in renal cell carcinoma at the 2017 Kidney Cancer Association symposium in Miami, FL.

Viraj A. Master of Emory University discusses Neoadjuvant Presurgical Therapy for RCC: Lessons Learned at the 2017 Kidney Cancer Association symposium in Miami, FL.

Tim Eisen University of Cambridge discusses Perspective(s) on Adjuvant Trials at the 2017 Kidney Cancer Association symposium in Miami, FL.

Grant D Stewart BSc, MBChB, FRCSEd (Urol), PhD University Lecturer and Consultant in Urological Surgery, Academic Urology Group, University of Cambridge discusses Prospective surgical RCC research: challenges, pitfalls and opportunities at the 2017 Kidney Cancer Association symposium in Miami, FL.

Axel Bex, MD, PhD The Netherlands Cancer Institute Amsterdam, The Netherlands outlines the Challenges in SURTIME and CARMENA at the 2017 Kidney Cancer Association symposium in Miami, FL.

Mark W. Ball, MD Staff Clinician | Assistant Research Physician Urologic Oncology Branch National Cancer Institute National Institutes of Health discusses Imaging in Renal Cell Carcinoma: Novel Methods and Approaches at the 2017 Kidney Cancer Association symposium in Miami, FL.

Steven C. Campbell, MD, PhD Program Director, Vice Chairman Department of Urology Center for Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic discusses Determinants and Predictors of Renal Function after Renal Surgery at the 2017 Kidney Cancer Association symposium in Miami, FL.

Rodolfo Borges dos Reis MD; PhD. Head of Uro-oncology Ribeirão Preto Medical School The University of São Paulo answers teh question Cystic Renal Masses: What are we Really Talking About? at the 2017 Kidney Cancer Association symposium in Miami, FL.

R. Houston Thompson, MD Professor of Urology Mayo Clinic, Rochester, MN @HThompsonMD presents Guidelines on Managing SRMs: Compare and Contrast at the 2017 Kidney Cancer Association symposium in Miami, FL.

John T. Leppert, MD MS Associate Professor, Stanford University Director of Urologic Oncology, VA Palo Alto @johnleppert presents Nephrometry: 21st Century Phrenology at the 2017 Kidney Cancer Association symposium in Miami, FL.

Loren Tarantino, MS SMP Global Partner discusses Systems Thinking Approach to Strategic Management at the MOASC educational series on November 8th, 2017.

Roberta Buell Principal, On Point Oncology presents the Revenue Cycle State of the State: Where are we? How can we fight delays and denials? at the MOASC educational series November 8th, 2017.

Elaine L. Towle, CMPE Division Director, Analysis & Consulting Services Clinical Affairs provides an in-depth look at the MACRA Quality Payment Program and notes that Its not too late to participate in 2017. Presentation was given at the MOASC educational series in Anaheim, CA on November, 8th 2017.

Merrianne Do, Pharm D of Walgreen’s discusses it’s new pilot program for specialty oncology drugs at the MOASC educational series in Anaheim CA on November 8th, 2017

Andrew W. Hahn, MD University of Utah Huntsman Cancer Institute @onchahn discusses Predictive genomic markers of response to VEGF targeted therapy (TT) in metastatic renal cell carcinoma (mRCC): Role of VHL and TP53 mutation, and FLT1 germline variant

IRINA PROSKOROVSKY, MSC discusses Axitinib and Cabozantinib in the Treatment of Sunitinib-Refractory Patients With Metastatic Renal Cell Carcinoma (mRCC): Results of Matching-Adjusted Indirect Treatment Comparison (MAIC) Analysis of AXIS and METEOR Trials at the 2017 Kidney Cancer Association symposium in Miami, FL.

Laurence Albiges, MD, PhD Institut Gustave Roussy Villejuif, France gives an overview of TiNivo  A Phase Ib Dose Escalation Trial of Tivozanib and Nivolumab in Renal Cell Carcinoma at the 2017 Kidney Cancer Association symposium in Miami, FL.

Michael Roger Harrison, MD of Duke University presents Deferred Systemic Therapy (DST) for Metastatic Renal Cell Carcinoma: Preliminary Prospective Experience at the 2017 Kidney Cancer Association symposium in Miami, FL.

ALEXANDRA DRAKAKI, MD, PHD UNIVERSITY OF CALIFORNIA LOS ANGELES gives an overview of A Phase I, Open Label, Dose Escalation Study to Evaluate the Safety and Immune Activation of Adv-GM-CAIX Transduced Dendritic Cells in Patients with Metastatic Kidney Cancer at the 2017 Kidney Cancer Association symposium in Miami, FL.

Martin H. Voss, MD of Memorial Sloan Kettering outlines the DART Study: A phase 2 randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced renal cell carcinoma (RCC): Results from the part 2 placebo-controlled trial at the 2017 Kidney Cancer Association symposium in Miami, FL.

Paulo G. Bergerot, MD of City of Hope Comprehensive Cancer Center discusses Variations in treatment patterns for metastatic renal cell carcinoma mRCC between developing and developed countries at the 2017 Kidney Cancer Association symposium in Miami, FL.

Cristiane Decat Bergerot, Phd answers the question How should we deal with the psychological burden of mRCC? at the 2017 Kidney Cancer Association symposium in Miami, FL.

Bernard Escudier, Gustave Roussy, Villejuif, FRANCE answers the question How should we treat brain metastases from RCC? at the 2017 Kidney Cancer Association symposium in Miami, FL.

Hans Hammers MD, PhD UT Southwestern asks the question How should we Incorporate Radiotherapy in RCC Management? at the 2017 Kidney Cancer Association symposium in Miami, FL.

James Brugarolas, M.D., Ph.D. Chair, CDMRP Kidney Cancer Research Program Programmatic Panel discusses the CDMRP Kidney Cancer Research Program at the 2017 Kidney Cancer Association symposium in Miami, FL.

Igor Kuzmin, Ph.D. Translational Research Program (TRP) DCTD, NCI trp.cancer.gov asks the question Applying for a SPORE Grant: How to Improve Your Odds?

Tian Zhang, MD Assistant Professor of Medicine Duke Cancer Institute discusses VEGF TKI/immunotherapy combinations will become the standard of care soon at the 2017 Kidney Cancer Association symposium in Miami, FL.

Bradley A McGregor, MD Clinical Director Lank Center for Genitourinary Oncology Dana Farber Cancer Institute discusses TKI Monotherapy Still has a Role in mRCC Front-Line Therapy at the 2017 Kidney Cancer Association symposium in Miami, FL.

Brian I. Rini, M.D. Department of Solid Tumor Oncology Cleveland Clinic Taussig Cancer Center highlights Ipi / Nivo is the New Standard of Care in mRCC at the 2017 Kidney Cancer Association symposium in Miami, FL.

Jianjun Gao, MD, PhD Assistant Professor Genitourinary Medical Oncology of MD Anderson outlines a Discussion of Correlatives Associated with Presurgical Nivolumab + – Bevacizumab or Ipilimumab Trial in mccRCC at the 2017 Kidney Cancer Association symposium in Miami, FL.

Lauren C. Harshman, MD discusses EA8143 PROSPER RCC: The Potential For Discovery through Correlatives at the 2017 Kidney Cancer Association symposium in Miami, FL.

Brian Shuch, MD of the Yale School of Medicine discusses the Biomarker Analysis of MET Alterations and Papillary Subtype in S1500 at the 2017 Kidney Cancer Association symposium in Miami, FL.

Mark Larkin, Director, Vitaccess gives an overview of the Kidney Cancer Association Digital Registry at the 2017 Kidney Cancer Association symposium in Miami, FL.

Laurence Albiges of Gustave Roussy, Villejuif, France discusses Non clear cell RCC Bridging Translational Data to the clinic Papillary RCC at the 2017 Kidney Cancer Association symposium in Miami, FL.

Gabriel Malouf, MD of Pitié-Salpêtrière Hospital University Pierre and Marie Curie discusses Collecting Duct Carcinomas at the 2017 Kidney Cancer Association symposium in Miami, FL.

James J. Hsieh MD of Siteman Cancer Center, Washington University discusses how to classify the unclassified renal cell carcinoma at the 2017 Kidney Cancer Association symposium in Miami, FL.

Gilberto de Lima Lopes, MD discusses the Impact of Geographic Distribution on Outcome in Cancer Africa & Asia at the 2017 Kidney Cancer Association Symposium in Miami FL.

Andr̩ P. Fay, MD, PhD, Professor, PUCRS School of Medicine Chief, Medical Oncology Department РHospital Ṣo Lucas da PUCRS discusses the Impact of Geographic Distribution on Outcome in mRCC-Latin America & South America at the 2017 Kidney Cancer Association symposium in Miami, FL.

Raje, Noopur MD of the Massachusetts General Hospital Cancer Center highlights that denosumab now gives clinicians more choices for treating multiple myeloma.

Raje, Noopur MD of the Massachusetts General Hospital Cancer Center discusses the next steps for Denosumab at the Lymphoma-Myeloma 2017 meeting in New York.

Raje, Noopur S., MD from Massachusetts General Hospital Cancer Center asks the question is it possible to switch from one bone targeting agent to another in multiple myeloma?

Raje, Noopur, MD of Massachusetts General Hospital Cancer Center discusses if it is possible to switch from one bone targeting agent to another in Multiple Myeloma?

Robert G. Uzzo, MD of Fox Chase Cancer Center presents his thoughts on the Cost Effectiveness in Renal Cell Carcinoma – What is Value and Who gets to decide? at the 2017 Annual Kidney Cancer Association in Miami, FL

Noopur Raje, MD of Massachusetts General Hospital Cancer Center outlines how the recently released economic analysis of Denosumab v. Zoledronic Acid found that Denosumab was overall more cost effective. Dr. Raje presented these findings at the 2017 Lymphoma-Myeloma meeting in New York.

John L. Gore, MD, MS from the University of Washington discusses Quality Measures in Renal Cell Carcinoma at the Kidney Cancer Association 2017 annual meeting in Miami FL.

Maxine Sun, PhD, MPH of Dana-Farber Cancer Institute discusses the Utility Pitfalls and Perils of Using Secondary Data for RCC Research at the 2017 annual Kidney Cancer Association Symposium in Miami, FL.

Noopur Raje, MD of Massachusetts General Hospital Cancer Center discusses her findings in which Denosumab is favored in newly diagnosed multiple myeloma patients from a recent economic analysis of Denosumab v Zoledronic Acid in Multiple Myeloma at the 2017 Lymphoma and Myeloma meeting in New York.

Nizar M. Tannir, MD Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston accepts the 2017 Kidney Cancer Association’s Eugene P. Schonfeld Memorial Award and gives an emotional and heartfelt lecture entitled “My Journey in Rare Kidney Tumors”.

Walter Stadler, MD of The University of Chicago discusses the Correlatives Associated with Bevacizumab/Atezolizumab at the annual 2017 Kidney Cancer Association symposium in Miami, FL

Andrew Fabiano, MD, is the Director of the Spinal Oncology Center at Roswell Park Cancer Institute. He shares with fellow physicians how to evaluate cancer patients who present with back pain. Dr. Fabiano discusses when to suspect spinal metastatic disease along with imaging and treatment options. This video originally appeared on www.reachmd.com and is jointly presented by Roswell Park Cancer Institute and Prova Education.

Ronald Alberico, MD, Director, Neuroradiology/Head & Neck at Roswell Park Cancer Institute presents for fellow physicians on identifying patients who may benefit from kyphoplasty and vertebroplasty. This video originally appeared on www.reachmd.com and is jointly presented by Roswell Park Cancer Institute and Prova Education.

What is next-generation sequencing and what is its annotation process? Carl Morrison, MD, DVM, Executive Director of the Center for Personalized Medicine, Clinical Chief, Department of Pathology & Laboratory Medicine, shares with physicians. This video originally appeared on www.reachmd.com and is jointly presented by Roswell Park Cancer Institute and Prova Education.

Khurshid Guru, MD, Chair, Department of Urology and Director, Robotic Surgery at Roswell Park Cancer Institute offers advice for physicians about choosing a cancer surgeon, referring patients to the right institution, and how to measure quality of surgery. This video originally appeared on www.reachmd.com and is jointly presented by Roswell Park Cancer Institute and Prova Education.

Gurkamal Chatta, MD, Clinical Chief of Genitourinary Medicine, presents on immuno-oncology, new immunotherapy cancer treatments and how the immune system responds to cancer. This video originally appeared on www.reachmd.com and is jointly presented by Roswell Park Cancer Institute and Prova Education.

Drs. Kunle Odunsi and Richard Koya provide details on a first-of-its-kind cancer immunotherapy clinical trial, available only at Roswell Park.This clinical trial was recently featured in a three-part series on our blog. Part 1: https://goo.gl/bdxjbM Part 2: https://goo.gl/MrmKGm Part 3: https://goo.gl/y2cDJU

Dr. Jack West reviews the key differences between findings that are worthy of clinical research and those that should be broadly adopted as a standard of care in cancer treatment, and differences in practice in academic vs. community practice.

In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Ji?í Schwarz discusses challenges in the management of essential thrombocythemia. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.

In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Andreas Reiter discusses the biology and therapy of eosinophilic neoplasms. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.

In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Jean Luc Villeval discusses the mechanisms of bone marrow fibrosis in patients with myelofibrosis. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.

In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Radek C. Skoda discusses new mouse models of myeloproliferative neoplasms (MPN). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.

In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Astrid Olsnes Kittang discusses the role of the immune system in the pathogenesis of myelodysplastic syndromes (MDS). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.

In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Carmen Aanei elucidates recent advances in the understanding of the myelodysplastic syndromes (MDS) microenvironment. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.

Dr. Jack West reviews evidence that a subset of patients with advanced NSCLC demonstrate “hyper-progressing disease” (HPD), worsening cancer at a faster rate, on immune checkpoint inhibitor therapy, more commonly than seen in patients on chemotherapy.

With the knowledge clinicians are gaining about the driver mutations of myeloproliferative neoplasms (MPNs), JAK inhibitors have become more recognized as a personalized, targeted therapy. But how do JAK inhibitors actually work? Dr. David Snyder from City of Hope explains what these medicines actual inhibit and goes on to discuss different variations of JAK inhibitors. Dr. Snyder shares information about approved JAK inhibitors and others in clinical trials, such as the PAC203 trial for pacritinib. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Interested in learning more about developing options to treat myeloproliferative neoplasms (MPNs)? Treating MPNs isnt a one-size-fits-all approach, and research done through clinical trials continues to expand the treatment arsenal. MPN experts Dr. Bart Scott of Seattle Cancer Care Alliance and Dr. David Snyder from City of Hope discuss potential new treatment options currently in development and clinical trials. Tune in to hear the latest. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Ludovic Bourre, Director of Scientific Engagement for Crown Bio Science gives a quick outline on why he feels T cell Co-Stimulation is important in immuno-oncology

Anti-OX40 has been demonstrated to improve tumor free survival in mice and is now moving past the first Phase 1 study. Ludovic Bourre, Director of Scientific Engagement for Crown Bio Science outlines the what has been seen so far with OX40.

Ludovic Bourre, Director of Scientific Engagement for Crown Bio Science gives an overview of the Phase 1 Study of Anti-OX40 in Patients With Metastatic Advanced Cancer and it’s conclusions.

Dr. Jack West reviews new findings highlighting the utility of using the biomarker tumor mutation burden (TMB) to predict which patients with small cell lung cancer (SCLC) will benefit from nivolumab or the combination of nivolumab with ipilimumab.

In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Alessandro M. Vannucchi discusses the future of experimental therapeutics for the treatment of myeloproliferative neoplasms (MPN). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.

In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Srdan Verstovsek discusses therapeutic insights into the clonal evolution of myeloproliferative neoplasms to accelerate of blastic phase. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.

In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Claire Harrison outlines her approach to the management of myelofibrosis. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.

In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Hans Michael Kvasnicka discsuses myelofibrosis marrow morphology and the key takeaways from the WHO 2016 diagnostic update. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.

In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Jaroslav Cermak discusses new opportunities resulting from the utilization of experimental therapeutics for myelodysplastic syndromes (MDS). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.

In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Aristoteles Giagounidis discusses the optimal use of lanalidomide as therapy for myelodysplastic syndromes (MDS). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.

In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Norbert Gattermann discusses iron chelation therapy for myelodysplastic syndromes (MDS). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.

In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Eva Hellström-Lindberg outlines her approach to the management of myelodysplastic syndromes (MDS). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.

In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Austin G. Kulasekararaj discusses the difference between hypocellular MDS and aplastic anemia, with emphasis on diagnosis and therapy. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.

In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Martin Griesshammer outlines his view on the current and future use of JAK inhibitors for essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF).Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology Also Recommended: Myelofibrosis Danazol vs Momelotinib a JAK inhibitor© 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Axel Grothey argues that circulating tumor DNA is ready to guide adjuvant therapy in colon cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Christopher L. Hallemeier argues that observation without surgery is not reasonable for rectal cancers that have achieved a clinical CR. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Julio Garcia-Aguilar argues that observation without surgery is reasonable for rectal cancers that have achieved a clinical CR. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Scott Kopetz discusses the difference in the sided-ness of colon cancers and whether biomarkers or biology are more relevant in determing therapy. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Axel Grothey argues that immunotherapy is the optimal treatment for refractory colorectal cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Eric Van Cutsem argues that TAS-102 or regorafenib are the optimal treatment for refractory colorectal cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Eric Van Cutsem argues that EGFR antibodies are mandatory targeted therapy for RAS/BRAF wild-type left sided colon cancers. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Axel Grothey argues that either bevacizumab or EGFR antibodies are the preferred targeted therapy for RAS/BRAF wild-type left sided colon cancers. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Jonathan Strosberg provides an update in the management of neuroendocrine cancers. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Scott Kopetz provides an update to advances in liquid biopsies and their relevance to the treatment of GI cancers. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

Dr. Aly-Khan Lalani, MD highlights a study he presented at ESMO 2017 about the usefulness Neutrophil-to-lymphocyte ratio (NLR) and how they might be a good prognosticator in mRCC. Below is an overview of the study and it’s findings. RESULTS: Table 2. Association of NLR at baseline, at 6-weeks, and change at week 6 (±2) with treatment outcomes in multivariable Cox and Logistic regression models BACKGROUND: Inflammation is a hallmark of solid tumors, where neutrophilia occurs as an inflammatory response and may suppress the cytolytic activity of immune cells such as lymphocytes, natural killer cells, and activated T cells1 Elevated NLR…

Dr. Aly-Khan Lalani, MD gives an overview of the advancements in Kidney Cancer presented at ESMO 2017 including the Cabosun and Checkmate 214 trial results. CABOSUN Results: The Alliance for Clinical Trials in Oncology as part of Exelixis collaboration with the National Cancer Institutes Cancer Therapy Evaluation Program (NCI-CTEP). The data presented at ESMO 2017 included the analysis from a blinded independent radiology review committee (IRC), which confirmed the primary efficacy endpoint results of investigator-assessed progression-free survival (PFS), as well as an updated investigator-assessed analysis. Per the IRC analysis, cabozantinib demonstrated a clinically meaningful and statistically significant 52 percent reduction…

Dr. Aly-Khan A. Lalani, MD discusses the impact of Neutrophil-to-lymphocyte ratio (NLR) in mRCC and it’s effect on outcomes. BACKGROUND: Inflammation is a hallmark of solid tumors, where neutrophilia occurs as an inflammatory response and may suppress the cytolytic activity of immune cells such as lymphocytes, natural killer cells, and activated T cells1 Elevated NLR is associated with worse outcomes in several malignancies, including metastatic renal cell carcinoma (mRCC) patients treated with oral tyrosine kinase inhibitors (VEGF-TKIs)2 However, the utility of NLR in mRCC patients treated with conventional immune checkpoint blockade is not well characterized OBJECTIVES: To evaluate the association…

During this segment from the Living Well series, Dr. Bart Scott, breaks down whats occurring at a cellular level with an essential thrombocythemia (ET) diagnosis. Dr. Scott also discusses physical reactions patients may experience, common mutations seen in ET, and treatment options available to combat the disease. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Although essential thrombocythemia (ET) is generally thought of as a disease that only affects the middle age and elderly population, but it has been observed in young adults too. Dr. Naveen Pemmaraju, a specialist at The University of Texas MD Anderson Cancer Center, explains what treatment options are available and how the livelihoods of youth are affected. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

The approvals of palbociclib and ribociclib, the first cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, provided advanced or metastatic hormone-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer patients with promising new treatment options. With a third CDK4/6 inhibitor, abemaciclib, approved in late September 2017, this class of therapy has become the new standard of care for HR+/HER2- breast cancer, which comprises the majority (approximately 75%) of all breast cancer cases. This interactive activity features Drs. Howard J. Burstein and Kimberly L. Blackwell discussing practical aspects of using this class of agents as first-line therapy in HR+/HER2- advanced or…

In this Velocity Vlog activity, Dr. Howard L. Kaufman of the Rutgers Cancer Institute contextualizes updates to the standard of care, relays the latest developments in immunotherapy, and offers insight into best practices for the incorporation of novel agents in your clinical practice. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7265 © 2017 Imedex, LLC.

In this Velocity Vlog activity, Dr. Paul Nghiem of the University of Washington shares emerging data and expert analysis about diagnosis, the emergence of immunotherapy as a viable therapeutic option, and the evolving standard of care for MCC. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7264 © 2017 Imedex, LLC.

The approvals of palbociclib and ribociclib, the first cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, provided advanced or metastatic hormone-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer patients with promising new treatment options. With a third CDK4/6 inhibitor, abemaciclib, approved in late September 2017, this class of therapy has become the new standard of care for HR+/HER2- breast cancer, which comprises the majority (approximately 75%) of all breast cancer cases. This interactive activity features Drs. Howard J. Burstein and Joyce O’Shaughnessy discussing practical aspects of using this class of agents as second-line therapy in HR+/HER2- advanced or metastatic…

Dr. Jack West reviews new evidence providing long-needed guidance on what patient surveillance after potentially curative surgery for early lung cancer makes a difference. The IFCT-0302 trial tests a minimal vs. maximal approach to answer that question.

Dr. Jack West assesses the merits of a combination of chemotherapy with pembrolizumab (Keytruda) based on the evolving efficacy data, especially the maturing results for overall survival, with longer follow-up of the KEYNOTE-021g trial.

How do you know if your MPN is progressing? Will it show in your blood work or will symptoms increase? Physician assistant, Lindsey Kalhagen, discusses progression and what might indicate a need for an adjustment in treatment. Although it can be difficult to differentiate side effects from medications and symptoms, its important for patients to monitor physical changes that could signify disease progression. Watch now to learn how paying close attention to symptoms, observing changes, and communicating with your provider can improve outcomes. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on…

Scott S. Tykodi MD of Seattle Cancer Care Alliance notes that the data from Checkmate 214 is clear that overall high grade side effects are better with immunotherapy.

Michael Needle, MD and Chief Medical Officer for AVEO Oncology gives an update for the Phase 3 TIVO-3 trial, a randomized, controlled,multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).

Scott S. Tykodi, MD of Seattle Cancer Care Alliance discusses the recently released Checkmate 214 data and how favorable RCC patients may be better served staying on targeted therapies rather than immunotherapy treatments.

Michael N. Needle, MD, and Chief Medical Officer of AVEO Oncology goes over the TIVO-1 Trial results first released in 2014. On August 28, 2017 it was announces that Tivozanib (FOTIVDA®) has been approved in the EU for RCC patients.

Dr. Scott S. Tykodi, MD reveals the results of the Checkmate – 214 trial with combined immunotherapy nivolumab plus ipilimumab and explains the positive results on objective response rate and prolonged progression-free survival compared to sunitinib in intermediate- and poor-risk patients with previously untreated advanced or metastatic renal cell carcinoma.

Michael Needle, MD and Chief Medical Officer of AVEO Oncology goes over why and how Tivozanib (FOTIVDA(R)) was given approval in the European Union for the treatment of advanced renal cell carcinoma.

K. Robert Shen, MD of of the Mayo Clinic in Rochester, MN discusses what to do with an esophageal cancer patient. When to use surgery versus induction therapy?

Patients often struggle with the decision to seek an opinion elsewhere. Is your own doctors opinion enough? Will you offend your doctor by getting a second opinion? In this segment, Dr. Brady Stein and Dr. Naveen Pemmaraju, both experts at academic medical centers, weigh in on this important decision. The doctors share their perspective on second opinions, why it matters with rare conditions, and advice for how to seek consultation with another doctor. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Dr. Jack West reviews the important, clinically relevant results of the CheckMate-153 trial that asks whether there is a value in continuing an immune checkpoint inhibitor in patients with advanced NSCLC doing well on immunotherapy.

Dr. Jack West summarizes the likely practice-changing results of the FLAURA trial of osimertinib vs. standard of care EGFR TKI therapy (gefitinib or erlotinib) as first line treatment for patients with EGFR mutation-positive NSCLC.

Dr. Jack West reviews data from ESMO 2017 & the NEJM paper on the PACIFIC trial of durvalumab vs. placebo as consolidation after chemoradiation for patients with unresectable stage III NSCLC, focusing especially on why these results are practice-changing.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. David H. Ilson argues that peri-operative chemotherapy is the standard of care. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Jonathan Strosberg argues that there is not a role for the surgical management of metastatic neuroendocrine cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Michael A. Choti argues that there is a role for surgical management of metastatic neuroendocrine cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Zsofia K. Stadler assesses the state of knowledge regarding hereditary syndromes in GI cancer, and proffers who should be tested and why. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Scott Kopetz provides an update on novel therapies for GI cancers. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Tanios S. Bekaii-Saab argues that the utilization of novel targets such as HER2 are not ready for prime time in the treatment of colorectal cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Neil H. Segal provides an update on the use of immunotherapy in the treatment of GI cancers. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Zsofia K. Stadler provides an update on the role of aspirin therapy in both GI cancer survivors and the general population. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

Dr. Jack West explains the potential value PD-L1 expression during the initial workup of patients with advanced NSCLC, in the face of a broad FDA approval for chemo/immunotherapy regardless of PD-L1 status in patients with advanced non-squamous NSCLC.

Held on 29 June 2017 in Barcelona, Spain, the Optimizing the Continuum of Care for Patients with Pancreatic Cancer symposium explored updated standards of care for treatment sequencing for pancreatic carcinoma. Utilizing a case based approach, this activity assesses the use of adjuvant chemotherapy at relapse, examines the optimal approach for patients with borderline resectable disease, and probes how the management of locally advanced pancreatic cancer impacts treatment decisions in the metastatic setting. This symposium was organized by: Celgene International Sàrl. Activity Disclaimer This satellite symposium was held in conjunction with the ESMO 19th World Congress on Gastrointestinal Cancer. The…

Dr. Jack West reviews data from pivotal trials showing that platforms that enable better communication between the cancer patient and the clinic lead to better clinical outcomes, including longer overall survival.

K. Robert Shen, MD, of the Mayo Clinic in Rochester, MN discusses how a new study highlights how estrogen could potentially be protective for some forms of cancers including esophageal cancer. See Report Below: Female patients with locally advanced esophageal cancer that is treated with chemotherapy and radiation therapy before surgery are more likely to have a favorable response to the treatment than male patients are, and women are less likely to experience cancer recurrence, according to a study published online today in The Annals of Thoracic Surgery. Esophageal cancer is one of the deadliest cancers in the world, said…

Professor Gareth Thomas at the University of Southampton, United Kingdom discusses the next steps for the preclinical models of GKT831

Hagop M. Kantarjian, MD of MD Anderson Cancer Center goes over some possible next steps for Inotuzumab after it has received FDA approval for acute

Hagop M. Kantarjian, MD of MD Anderson Cancer Center discusses how veno occlusive disease may cause complications while using inotuzumab if not identitified in adult acute lymphoblastic leukemia patients.

Hagop M. Kantarjian, MD of MD Anderson Cancer Center states “We are witnessing a slow motion revolution in ALL” talking about Inotuzumab.

Professor Gareth Thomas at the University of Southampton, United Kingdom discusses the relatively well tolerated GKT831 in other disease states.

K. Robert Shen, MD of Mayo Clinic in Rochester reports that female patients with locally advanced esophageal cancer that is treated with chemotherapy and radiation therapy before surgery are more likely to have a favorable response to the treatment than male patients are, and women are less likely to experience cancer recurrence, according to a study published in The Annals of Thoracic Surgery. Study Results Below: Esophageal cancer is one of the deadliest cancers in the world, said senior author K. Robert Shen, MD, of the Mayo Clinic in Rochester, MN. It affects men and women differently. Men are more…

Hagop M. Kantarjian, MD of MD Anderson Cancer Center’s Department of Leukemia says now that Besponsa or Inotuzumab is FDA approved that clinicians clinicians treating refractory relapse ALL should consider Inotuzumab for their patients.

Professor Gareth Thomas at the University of Southampton, United Kingdom discusses his preclinical research about cancer associated fibroblasts (CAFs) and notes that inhibiting CAFs are not sufficient to stop cancer growth.

Hagop M. Kantarjian, MD of MD Anderson Cancer Center’s Department of Leukemia states the median survival rate nearly doubles combining Inotuzumab with chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Professor Gareth Thomas of University of Southampton discusses data in multiple preclinical models that showed GKT831 efficiently targeted cancer associated fibroblasts (CAFs) and delayed tumor growth.

Dr. Jack West reviews the promise of combinations of immunotherapies for advanced NSCLC and the implications for the field of the initial report that the MYSTIC trial failed to show an improvement in progression-free survival with an IT combination.

Dr. Jack West discusses the implications of a positive FLAURA trial, which revealed a significant improvement in progression-free survival for first line osimertinib over gefitinib or erlotinib in patients with EGFR mutation-positive advanced NSCLC.

Dr. Jack West reviews the potential new role for immunotherapy in locally advanced NSCLC based on the early report that the PACIFIC trial of durvalumab after chemo/radiation is positive for a significant improvement in progression-free survival.

Hagop M. Kantarjian, MD of MD Anderson Cancer Center’s Department of Leukemia gives the trial overview and conclusions of Pfizer’s newly approved FDA CD22-directed antibody-drug conjugate Besponsa (Inotuzumab Ozogamicin) for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

In this presentation from the Treatment Dilemmas in Polycythemia Vera: Leveraging Evidence and Clinical Experience to Improve Patient Care symposium, Dr. Srdan Verstovsek discusses the clinical data relevant to the use of opeginterferon for patients with polycythemia vera. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7261 © 2017 Imedex, LLC.

In this presentation from the Treatment Dilemmas in Polycythemia Vera: Leveraging Evidence and Clinical Experience to Improve Patient Care symposium, Dr. Elizabeth O. Hexner discusses when to move from hydroxyurea to a second-line therapy. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7261 © 2017 Imedex, LLC.

In this presentation from the Treatment Dilemmas in Polycythemia Vera: Leveraging Evidence and Clinical Experience to Improve Patient Care symposium, Dr. Brady Lee Stein discusses whether our current understanding of the prognostication and initiation of therapy for PV patients is correct. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7261 © 2017 Imedex, LLC.

In this discussion, recorded during the 2017 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, held August 4-5, 2017 in Philadelphia, the Congress co-chairs highlight the key points presented during the meeting, with the aim of sharing updates that will help you enhance your clinical practice. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7260 © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Tanios S. Bekaii-Saab argues that there is no standard second line therapy for the treatment of hepatocellular carcinoma (HCC). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Ghassan Abou-Alfa argues that regorafenib should be the standard second line therapy for hepatocellular carcinoma (HCC). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Mark A, Schattner provides an update into the novel endoscopic management of pancreatic biliary cancers. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Eileen O’Reilly provides an update in novel targeted therapy for pancreatic cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Tanios S. Bekaii-Saab argues that gemcitabine/capecitabine is the optimal adjuvant chemotherapy regimen for resected pancreatic cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Jordan Berlin argues that gemcitabine/nab-paclitaxel is the optimal adjuvant chemotherapy for resected pancreatic cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Christopher H. Crane argues that preoperative chemotherapy plus radiation is the optimal neoadjuvant strategy for pancreatic cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Jordan Berlin argues that chemotherapy alone is the optimal neoadjuvant strategy for pancreatic cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Christopher L. Hallemeier argues that surgery is not required after chemoradiotherapy for squamous cancer of the esophagus. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Christopher H. Crane argues that post-operative radition therapy is required in this setting. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

At a recent town meeting in partnership with Robert H. Lurie Comprehensive Cancer Center in Chicago, Dr. Brady Stein helps viewers understand what should be considered when choosing a treatment plan for those with essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF). Dr. Stein talks about factors such as symptoms and risk. He goes on to provide considerations for each of the myeloproliferative neoplasms (MPNs).Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/ +patientpowerinfo  

In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Ghassan Abou-Alfa provides an update in novel treatments for hepatocellular carcinoma (HCC) in the era of hepatitis C therapies. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=GICANCER © 2017 Imedex, LLC.

In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Umberto Ricardi discusses the use of loco-regional therapy to treat brain metastases. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Suresh Senan discusses new radiotherapy techniques for the treatment of lung cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Jesus Corral discusses how best to manage adverse effects when utilizing immunotherapy for the treatment of lung cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Joachim G. Aerts discusses the utilization of immune checkpoint inhibitors in the treatment of lung cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Sandrine Aspeslagh elucidates the basis for immunotherapy in lung cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Paul Van Schil arguest that trimodality therapy is the optimal approach for stage III non-small cell lung cancer (NSCLC). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Ugo Pastorino discusses primary and secondary prevention of lung cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Stefano Gasparini discusses how best to use endobronchial and other techniques to optimize diagnosis and therapy in lung cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Ramon Rami-Porta discusses updates on the TNM staging system. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

Jeffrey E. Lancet, MD of Moffitt Cancer Center discusses the next steps and future development for vyxeos in AML, which include a better understanding of the drug and its impact on overall survival in other subsets of AML.

Jeffrey E. Lancet, MD of Moffitt Cancer Center gives an overview of a phase 3 randomized trial, which focused on the use of vyxeos (CPX-351) compared to cytarabine and daunorubicin (7+3) in older patients with therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Jeffrey E. Lancet, MD of Moffitt Cancer Center discusses the impact of vyxeos on future clinical practice.

Jeffrey E. Lancet, MD of Moffitt Cancer Center discusses common questions hes been asked regarding the safety and efficacy of vyxeos in AML patients.

Karen Smith, MD outlines the safety and efficacy of Vyxeos the newly approved chemotherapy for the treatment of adults with newly-diagnosed t-AML or AML-MRC. The FDA approval is based on data from a pivotal Phase 3 clinical trial that evaluated the efficacy and safety of Vyxeos compared to cytarabine and daunorubicin (7+3) in 309 patients 60 to 75 years of age with newly diagnosed t-AML or AML-MRC. In the Vyxeos arm, patients received 44mg/100mg per m2 (daunorubicin and cytarabine) liposome intravenously via a 90 minute infusion on days 1, 3 and 5 of induction (days 1 and 3 if a…

Karen Smith answers some common questions and concerns about the newly FDA approved Vyxeos for the treatment of adults with newly-diagnosed t-AML or AML-MRC. The FDA approval is based on data from a pivotal Phase 3 clinical trial that evaluated the efficacy and safety of Vyxeos compared to cytarabine and daunorubicin (7+3) in 309 patients 60 to 75 years of age with newly diagnosed t-AML or AML-MRC. In the Vyxeos arm, patients received 44mg/100mg per m2 (daunorubicin and cytarabine) liposome intravenously via a 90 minute infusion on days 1, 3 and 5 of induction (days 1 and 3 if a…

The U.S. Food and Drug Administration (FDA) has approved VyxeosTM (daunorubicin and cytarabine) liposome for injection for the treatment of adults with two types of Acute Myeloid Leukemia (AML), a rapidly progressing and life-threatening blood cancer. Vyxeos is indicated for the treatment of adults with newly-diagnosed t-AML or AML-MRC. The FDA approval is based on data from a pivotal Phase 3 clinical trial that evaluated the efficacy and safety of Vyxeos compared to cytarabine and daunorubicin (7+3) in 309 patients 60 to 75 years of age with newly diagnosed t-AML or AML-MRC. In the Vyxeos arm, patients received 44mg/100mg per…

Dr. Catriona Jamieson, from Moores Cancer Center at UC San Diego Health, joined Patient Power to discuss considerations when choosing to participate in a clinical trial. Dr. Jamieson sheds light on the necessity of ongoing MPN clinical trials, particularly for myelofibrosis, as well as how to talk to your doctor about this treatment option. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Dr. Alex Spira, Director of the Virginia Cancer Specialist Research Institute and ASCO President Dr. Bruce Johnson, discuss research around promising clinical trials to help patients and care partners learn how to be proactive in order to get tomorrows medicine today. Leading patient advocate Matt Ellefson of SURVIVIEiT® joins the panel to share his passion and tips for making sure patients advocate for themselves from the start. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Daniela Bota, MD of UC Irvine Health discusses the use of neratinib and capecitabine in patients with breast cancer brain metastases at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA. Abstract 1005: TBCRC 022: Phase II Trial of Neratinib + Capecitabine for Patients (pts) with Human Epidermal Growth Factor Receptor 2 (HER2+) Breast Cancer Brain Metastases (BCBM)

Daniela Bota, MD of UC Irvine Health discusses the results of nivolumab versus nivolumab plus ipilimumab in patients with Melanoma at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA. Abstract 9508: A Randomized Phase II Study of Nivolumab or Nivolumab Combined with Ipilimumab in Patients (pts) with Melanoma Brain Metastases (mets): The Anti-PD1 Brain Collaboration (ABC)

Daniela Bota, MD of UC Irvine Health gives an overview of the final results of the TAVAREC trial, which studied temozolomide and bevacizumab in patients with glioma. This was recorded at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA. Abstract 2009: Final Results of the EORTC Brain Tumor Group Randomized Phase II TAVERAC Trial on Temozolomide with or without Bevacizumab in 1st Recurrance Grade II/III Glioma without 1p/19q co-deletion

Daniela Bota, MD of UC Irvine Health discusses a phase II clinical trial called the CEVOREM study, which focused on everolimus and octreotide in patients with meningioma. This was recorded at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA. Abstract 2011: A Phase II of Everolimus and Octreotide for Patients with Refractory and Documented Progressive Meningioma (CEVOREM)

Daniela Bota, MD of UC Irvine Health gives an overview of the AURA3 trial and the use of osimertinib in patients with advanced non-small cell lung cancer at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA. Abstract 9005: CNS Response to Osimertinib in Patients (pts) with T790M-Positive Advanced NSCLC: Data from a Randomized Phase III Trial (AURA3)

Daniela Bota, MD of UC Irvine Health gives her take on Senator John McCain’s recent diagnosis of glioblastoma. She further explains the common symptoms of glioblastoma, the importance of participating in clinical trials, and the most effective and common treatment options for those who are affected by this specific cancer.

Viola Zhu, MD, PhD of UC Irvine Health discusses the CTONG 1104 trial and the use of gefitinib for adjuvant treatment of patients with resected EGFR+ non-small cell lung cancer. This was recorded at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA. Abstract 8500: CTONG 1104: Adjuvant Treatment with Gefitinib in Resected EGFR+ NSCLC.

Viola Zhu, MD, PhD of UC Irvine Health discusses the AvaALL trial and the use of bevacizumab beyond progression in patients with non-small cell lung cancer. This was recorded at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA. Abstract 90040: AvaALL: Use of Bevacizumab Beyond Progression

Viola Zhu, MD, PhD of UC Irvine Health gives an overview of the ARCHER 1050 trial in EGFR+ non-small cell lung cancer at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA. Abstract LBA9007: ARCHER 1050: Dacomitinib versus Gefitinib in EGFR+ NSCLC at the First Line Setting

Viola Zhu, MD, PhD of UC Irvine Health discusses the ALEX trial and the use of alectinib and crizotinib in ALK+ non-small cell lung cancer at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA. Abstract LBA9008: ALEX: Alectinib versus Crizotinib in ALK+ NSCLC at the First-Line Setting.

Rita Mehta, MD of UC Irvine Health discusses the take-home message of PALOMA-1 and the impact on clinical practice at the 2017 MOASC Spotlight on Oncology in Huntington Beach, CA. Abstract 1001: Overall Survival: Palbociclib in Combination with Letrozole versus Letrozole Alone for Frontline Treatment of ER+/HER2-Advanced Breast Cancer PALOMA-1; TRIO-18

Rita Mehta, MD of UC Irvine Health gives an overview of the PALOMA-1 trial and the use of palbociclib and letrozole in the treatment of ER+ and HER2-advanced breast cancer. This was recorded at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA. Abstract 1001: Overall Survival: Palbociclib in Combination with Letrozole versus Letrozole Alone for Frontline Treatment of ER+/HER2-Advanced Breast Cancer PALOMA-1; TRIO-18

Rita Mehta, MD of UC Irvine Health gives an overview of the OlympiAD study, which focuses on the use of olaparib in HER2 negative metastatic breast cancer. This was recorded at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA. Abstract LBA4: OlympiAD: Olaparib versus Chemotherapy in HER2 Negative Metastatic Breast Cancer and a Germline BRCA Mutation

Rita Mehta, MD of UC Irvine Health discusses the MONARCH 2 trial and the use of abemaciclib and fulvestrant in advanced HR+/HER2 negative breast cancer progressing patients following prior endocrine therapy. This was recorded at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA. Abstract 1000: MONARCH 2: Abemaciclib with Fulvestrant in Patients withs HR+/HER2-Advanced Breast Cancer who Progressed on Endocrine Therapy

Rita Mehta, MD of UC Irvine Health gives an overview of the APHINITY trial and the use of pertuzumab as adjuvant therapy for patients with HER2+ early breast cancer. This was recorded at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA. Abstract: LBA500: APHINITY trial (BIG 4-11): Pertuzumab as Adjuvant Therapy in HER2-Positive Early Breast Cancer.

Farshid Dayyani, MD, PhD of UC Irvine Health discusses sidedness in colorectal cancer tumors at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA.